GlassScriptPhysician profile
Paul Rizk
NPI 1053816702
$6,766.77
in general payments reported to CMS, 2019-2025
23 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.60 · 2022: $1,494 · 2023: $1,896 · 2024: $2,267 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483 · Travel and Lodging: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,483.21 |
| Travel and Lodging | $729.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,598.01 | 2023-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $1,073.45 | 2023-2025 | Ams 700, Axonics, Lithovue |
| Stryker Corporation | $1,050.11 | 2022 | |
| Teleflex LLC | $429.45 | 2023-2025 | Urolift, Barrigel |
| Olympus America INC. | $389.37 | 2022-2025 | Itind System |
| Myriad Genetic Laboratories, INC. | $312.30 | 2023-2025 | Prolaris |
| Sumitomo Pharma America, INC. | $241.51 | 2023-2025 | Gemtesa |
| Urogen Pharma, INC. | $241.08 | 2020-2023 | Jelmyto |
| Endo USA, INC. | $222.48 | 2024-2025 | Xiaflex |
| Procept Biorobotics Corporation | $177.10 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Coloplast Corp | $176.83 | 2025 | |
| Medtronic, INC. | $156.40 | 2022-2025 | Interstim |
| Abbvie INC. | $140.46 | 2023-2025 | Lupron Depot, Botox |
| Laborie Medical Technologies Corp. | $109.60 | 2023 | |
| Janssen Biotech, INC. | $95.64 | 2023-2024 | Erleada |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $90.88 | 2022 | |
| Endo Pharmaceuticals INC. | $57.12 | 2024 | Xiaflex |
| Pfizer INC. | $55.18 | 2023-2024 | |
| Antares Pharma, INC. | $47.64 | 2024-2025 | Xyosted |
| Halozyme INC | $36.76 | 2023 | |
| Alnylam Pharmaceuticals INC. | $24.58 | 2023 | Oxlumo |
| Astellas Pharma US INC | $20.54 | 2025 | Padcev |
| Tolmar, INC. | $20.28 | 2025 | Eligard, Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rizk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.